Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women

Yoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, et al. | Science | 2021 | Evidence: moderate

Plain-language summary

Published 2021 in Science, this work by Yoshino M and collaborators tackles a specific question within benefits-focused NMN/NAD+ research.

Key findings reported by the authors

10 weeks of 250 mg/day NMN improved muscle insulin sensitivity in prediabetic postmenopausal women
First placebo-controlled NMN trial in women
Skeletal muscle insulin signalling and remodelling improved

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the moderate end of the evidence spectrum. Moderate-tier evidence usually means a small human trial or a well-designed mouse study; helpful for hypothesis-building but not for hard recommendations. Findings here are most directly relevant to benefits decisions, with secondary relevance to safety and dosage. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.

Where we cite this paper

← Back to research index